Psychedelics Space Enters New Era as AbbVie Dives In

AbbVie is making a major push into psychedelic therapeutics with its $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression asset, framed as a rebound after Lykos’ FDA rejection. The article links the renewed momentum to rising Phase III activity across the sector, with multiple companies competing for the first approvals. The piece situates the deal within broader big pharma interest, noting prior moves like Johnson and Johnson’s ketamine derivative Spravato and Japan-based Otsuka’s acquisition of Mindset Pharma with psilocybin-like assets. It also highlights ongoing pressure from regulatory and clinical trial realities, including how therapy components may affect labeling and study design, plus durability of response and double-blind challenges for psychedelic effects. Industry leaders argue the market may be ready once approved, citing provider openness and clinician interest due to rapid-acting potential in depression and other psychiatric disorders with unmet need. The article also points to dealmaking and strategic watchlists for other large pharma companies considering entry, while emphasizing transparency with FDA and public data sharing as key to de-risking the space.